Product Information
CARTIA XT 300 MG CAPSULE is a generic product labeled by Actavis Pharma, Inc., priced at $0.3020 per EA under NDC 62037060005. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jul 9, 1998. Its Orange Book therapeutic-equivalence code is AB3 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Actavis Pharma, Inc.NDC
62037060005
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DILTIAZEM HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA074752FDA Approved
7/9/1998
TE Code
AB3
On Market Since
7/9/1998
Pharmacological Classes
Price Statistics
The NADAC for CARTIA XT 300 MG CAPSULE has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 58.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3020 per EA |
|---|---|
| All-time high | $0.7789 (Mar 12, 2014) |
| All-time low | $0.2613 (Apr 19, 2023) |
| 52-week high | $0.3098 |
| 52-week low | $0.2943 |
| Median price | $0.4913 |
| Average price | $0.4851 |
| Largest weekly change | +35.3% (Aug 21, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 43% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Diltiazem Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Calcium Channel Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARTIA XT 300 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for CARTIA XT 300 MG CAPSULE, manufactured by Actavis Pharma, Inc., is $0.3020 per EA (NDC 62037060005), effective Sep 30, 2026.
How has the price of CARTIA XT 300 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for CARTIA XT 300 MG CAPSULE has declined 58.6%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CARTIA XT 300 MG CAPSULE?
Since Nov 28, 2013, the NADAC for CARTIA XT 300 MG CAPSULE has ranged from a low of $0.2613 (Apr 19, 2023) to a high of $0.7789 (Mar 12, 2014), with a median of $0.4913 per EA.
Are there cheaper alternatives to CARTIA XT 300 MG CAPSULE?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, DILTIAZEM 24HR ER 300 MG CAP, is $0.1729 per EA — about 43% below CARTIA XT 300 MG CAPSULE.
Who manufactures CARTIA XT 300 MG CAPSULE?
CARTIA XT 300 MG CAPSULE (NDC 62037060005) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.